Recombinant snake antivenoms get closer to the clinic.

Laustsen, Andreas H

Laustsen, Andreas H.

Affiliation

Laustsen AH; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, DK-2800, Denmark. Electronic address: ahola@bio.dtu.dk.

Trends Immunol ; 45(4): 225-227, 2024 Apr.

Article in En | MEDLINE | ID: mdl-38538486

ABSTRACT

ABSTRACT

Snakebite envenomings kill ~100 000 victims each year and leave many more with permanent sequelae. Antivenoms have been available for more than 125 years but are in need of innovation. A new study by Khalek et al. highlights broadly neutralizing human monoclonal antibodies (mAbs) that might be used to develop recombinant antivenoms with superior therapeutic benefits.

Subject(s)

Antivenins; Snake Bites; Humans; Animals; Antivenins/therapeutic use; Snake Bites/drug therapy; Antibodies, Monoclonal/therapeutic use; Snakes

Key words

Snakebite envenoming; antivenom; broadly-neutralizing antibodies; monoclonal antibodies; recombinant antivenom; snake venom toxins

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Snake Bites / Antivenins Limits: Animals / Humans Language: En Journal: Trends Immunol / Trends immunol / Trends in immunology Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Type: Article

Fulltext

XML

PubMed Links

Search on Google